Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Argan (AGX) Common Equity: 2010-2025

Historic Common Equity for Argan (AGX) over the last 15 years, with Oct 2025 value amounting to $419.7 million.

  • Argan's Common Equity rose 27.69% to $419.7 million in Q4 2025 from the same period last year, while for Oct 2025 it was $419.7 million, marking a year-over-year increase of 27.69%. This contributed to the annual value of $351.9 million for FY2025, which is 20.94% up from last year.
  • Per Argan's latest filing, its Common Equity stood at $419.7 million for Q4 2025, which was up 6.75% from $393.2 million recorded in Q3 2025.
  • Argan's Common Equity's 5-year high stood at $419.7 million during Q4 2025, with a 5-year trough of $271.7 million in Q4 2022.
  • For the 3-year period, Argan's Common Equity averaged around $323.2 million, with its median value being $300.6 million (2024).
  • Its Common Equity has fluctuated over the past 5 years, first declined by 22.31% in 2022, then increased by 27.69% in 2025.
  • Argan's Common Equity (Quarterly) stood at $349.8 million in 2021, then declined by 22.31% to $271.7 million in 2022, then grew by 4.82% to $284.8 million in 2023, then grew by 15.40% to $328.7 million in 2024, then rose by 27.69% to $419.7 million in 2025.
  • Its last three reported values are $419.7 million in Q4 2025, $393.2 million for Q3 2025, and $363.9 million during Q2 2025.